If it was presented correctly in the first place, it shouldn't have failed. The fact that an appeal (as a last ditch effort) had to be made at all, is the nail in Carter's coffin.
Money, time, flailing share price, etc., is the collateral damage to this drug failing the TGA approval process the first time around.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $207.5M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| ALA (ASX) Chart |
Day chart unavailable